Annalisa Jenkins, M.B.B.S., F.R.C.P.
Chief Executive Officer
Dr. Annalisa Jenkins is a life sciences thought leader with over 20 years of biopharmaceutical industry experience. Prior to joining PlaqueTec as CEO in November 2017, Dr. Jenkins served as president and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years – including serving as senior vice president and head of global medical affairs. Earlier in her career, Dr. Jenkins was a medical officer in the British Royal Navy during the Gulf Conflict, achieving the rank of surgeon lieutenant commander. Dr. Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOX Therapeutics Limited, Thrombolytic Strategies Incorporated, Cocoon Biotech Inc. (Non Executive Chair), OncoSec, Vium, Inc. (Executive Chair), and Silence Therapeutics (Non-Executive Chair). She also is a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), and serves on the board of the Center for Talent Innovation in the U.K. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.
Nick West, MD, FRCP
Chief Medical Officer
Nick is a Consultant Interventional Cardiologist at Papworth Hospital, Cambridge, the UK’s largest specialist Cardiothoracic Unit. He graduated in medicine from the University of Cambridge and undertook his cardiology training at the John Radcliffe Hospital, Oxford; he previously undertook research towards his doctoral thesis in the field of endothelial biology at both the University of Oxford and Duke University, North Carolina. He is a research-active clinician with extensive clinical trial experience in both industry-sponsored and investigator-initiated studies, with extensive track record of publication in intravascular imaging (IVUS, OCT), coronary physiology and novel medical devices, including bioabsorbable stents. He has previously been Clinical Lead for Interventional Cardiology at Papworth, Deputy Chair of the British Cardiovascular Society Acute Cardiac Care Working Group and a longstanding member of the Guidelines & Clinical Practice Committee. He has also acted as an expert advisor to NICE, peer-reviews for journals and is a faculty member at national and international Cardiology meetings.
Stephen Blatcher, PhD CEng MIMechE
Chief Operating Officer
Stephen has led the development of the LBS from concept to regulatory approval. He is currently responsible for managing the short run manufacture of the LBS. As Management Representative for PlaqueTec’s Quality Management System, Stephen also has responsibility for ensuring that PlaqueTec’s internal processes are appropriate to meet all operational requirements. Prior to co-founding PlaqueTec, Stephen spent 10 years in technology consultancy helping companies develop innovative medical products. He is named inventor on 10 patents and has a PhD in the field of orthopaedics. Stephen is chartered with the Institution of Mechanical Engineers.
Richard Owen, PhD
Chief Scientific Officer
Richard is a molecular biologist with twenty two years’ experience of developing complex biological products, managing projects and assessing both technologies and their markets. He is responsible for developing and executing the science demonstrating PlaqueTec’s impact on CAD. Prior to co-founding PlaqueTec, he worked at PA Consulting Group for eight years. Before PA, he developed diagnostic assays for the industrial sector at Celsis plc and clinical diagnostic assays for DAKO Ltd. He has a PhD in molecular microbiology and a degree in genetics and microbiology.